Nothing Special   »   [go: up one dir, main page]

DK1121102T3 - Liposomindesluttede topoisomeraseinhibitorer - Google Patents

Liposomindesluttede topoisomeraseinhibitorer

Info

Publication number
DK1121102T3
DK1121102T3 DK99954971T DK99954971T DK1121102T3 DK 1121102 T3 DK1121102 T3 DK 1121102T3 DK 99954971 T DK99954971 T DK 99954971T DK 99954971 T DK99954971 T DK 99954971T DK 1121102 T3 DK1121102 T3 DK 1121102T3
Authority
DK
Denmark
Prior art keywords
liposomes
liposome
enclosed
topoisomerase
topoisomerase inhibitors
Prior art date
Application number
DK99954971T
Other languages
English (en)
Inventor
Gail T Colbern
Peter K Working
James Lloyd Slater
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22301756&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1121102(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of DK1121102T3 publication Critical patent/DK1121102T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK99954971T 1998-09-16 1999-10-15 Liposomindesluttede topoisomeraseinhibitorer DK1121102T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10467198P 1998-09-16 1998-09-16
PCT/US1999/024228 WO2000023052A1 (en) 1998-09-16 1999-10-15 Liposome-entrapped topoisomerase inhibitors

Publications (1)

Publication Number Publication Date
DK1121102T3 true DK1121102T3 (da) 2003-08-11

Family

ID=22301756

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99954971T DK1121102T3 (da) 1998-09-16 1999-10-15 Liposomindesluttede topoisomeraseinhibitorer

Country Status (18)

Country Link
US (4) US6355268B1 (da)
EP (1) EP1121102B1 (da)
JP (1) JP2002527466A (da)
KR (1) KR100679906B1 (da)
CN (1) CN1205923C (da)
AT (1) ATE238039T1 (da)
AU (1) AU774715B2 (da)
BR (1) BR9914601A (da)
CA (1) CA2346879A1 (da)
DE (1) DE69907243T2 (da)
DK (1) DK1121102T3 (da)
ES (1) ES2198970T3 (da)
IL (1) IL142573A0 (da)
NO (1) NO20011844D0 (da)
NZ (1) NZ511112A (da)
PT (1) PT1121102E (da)
WO (1) WO2000023052A1 (da)
ZA (1) ZA200103063B (da)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142573A0 (en) * 1998-09-16 2002-03-10 Alza Corp Liposome-entrapped topoisomerase inhibitors
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
CA2376849C (en) * 1999-06-24 2008-10-14 Kyowa Hakko Kogyo Co., Ltd. Method of inhibiting leakage of drug encapsulated in liposomes
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
AU2001258106A1 (en) * 2000-05-11 2001-11-20 Celator Technologies Inc. Lipid carrier compositions for improved drug retention
US7452550B2 (en) 2000-06-30 2008-11-18 Hana Biosciences, Inc. Liposomal antineoplastic drugs and uses thereof
CA2412790C (en) * 2000-06-30 2012-11-06 Inex Pharmaceuticals Corporation Liposomal antineoplastic drugs and uses thereof
HUP0302352A3 (en) * 2000-11-09 2007-03-28 Neopharm Sn-38 lipid complexes and methods of use
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
WO2003075977A2 (en) 2002-03-05 2003-09-18 Cleveland State University Agglomerated particles for aerosol drug delivery
EP1393719A1 (en) * 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
US20070231379A1 (en) * 2002-08-29 2007-10-04 Slater James L Liposome-entrapped topoisomerase inhibitors
KR101133084B1 (ko) * 2002-12-31 2012-04-04 자이더스 비에스브이 파마 프라이빗 리미티드 장기간 순환성 비-페길레이티드 리포좀
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
EP1608338A1 (en) * 2003-04-02 2005-12-28 Celator Technologies Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
JPWO2004089419A1 (ja) * 2003-04-04 2006-07-06 国立大学法人 東京大学 抗ｍｔ−ｍｍｐモノクローナル抗体含有脂質膜構造体
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
JP2007522085A (ja) * 2003-06-27 2007-08-09 スミスクライン・ビーチャム・コーポレイション 安定化されたトポテカンリポソーム組成物および方法
CN100431525C (zh) * 2003-07-17 2008-11-12 台湾东洋药品工业股份有限公司 脂质体悬浮液制造方法及含该法所制脂质体悬浮液的产物
ES2321841T3 (es) 2003-08-26 2009-06-12 Smithkline Beecham Corporation Copolimeros heterofuncionales de glicerol y polietilenglicol, sus conjugados y composiciones.
AU2004283758A1 (en) * 2003-10-24 2005-05-06 Alza Corporation Preparation of lipid particles
CN100423778C (zh) * 2003-11-25 2008-10-08 上海复旦张江生物医药股份有限公司 用于上载抗肿瘤药物的脂质体载体及其制备方法和应用
JPWO2005053643A1 (ja) * 2003-12-01 2007-06-28 三菱ウェルファーマ株式会社 リポソーム
US20050129750A1 (en) * 2003-12-15 2005-06-16 Yu-Fang Hu Process for producing liposome suspension and product containing liposome suspension produced thereby
US20050129752A1 (en) * 2003-12-15 2005-06-16 Tty Biopharm Limited Company Use and manufacturing process for liposomal doxorubicin pharmaceutical composition
EP1547580A1 (en) * 2003-12-23 2005-06-29 MediGene Oncology GmbH Loading of a camptothecin drug into colloidal nanoparticles
EP1547582A1 (en) * 2003-12-23 2005-06-29 MediGene Oncology GmbH Method of producing lipid complexed camptothecin-carboxylate
CN1938048B (zh) * 2004-03-26 2010-05-12 泰尔茂株式会社 脂质体制剂
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
CA2566007C (en) 2004-05-03 2013-09-24 Hermes Biosciences, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
AU2011202665C1 (en) * 2004-05-03 2014-04-24 Ipsen Biopharm Ltd. Liposomes useful for drug delivery
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
AU2005249314B2 (en) * 2004-06-01 2008-09-11 Kabushiki Kaisha Yakult Honsha Irinotecan preparation
ES2562052T3 (es) * 2004-06-18 2016-03-02 Kabushiki Kaisha Yakult Honsha Preparación liposómica que contiene camptotecina ligeramente soluble en agua
WO2006017179A1 (en) 2004-07-09 2006-02-16 Robert Sabin Compositions and methods of use for treatment of mammalian diseases
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
US8318200B1 (en) * 2004-10-05 2012-11-27 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8663599B1 (en) * 2004-10-05 2014-03-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8318198B1 (en) * 2004-10-05 2012-11-27 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
AU2005302255A1 (en) * 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
EP1807051A2 (en) * 2004-11-05 2007-07-18 Inex Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
JP5110880B2 (ja) * 2004-11-18 2012-12-26 テルモ株式会社 医薬組成物、製剤および組み合わせ製剤
US20090104254A1 (en) * 2004-12-22 2009-04-23 Rutgers, The State University Of New Jersey Controlled Release Hydrogels
US20070254019A1 (en) * 2006-03-15 2007-11-01 William Zamboni Method for treating brain cancer
US20070259031A1 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
US20100047334A1 (en) * 2006-10-06 2010-02-25 Sofou Stavroula Ph sensitive liposome compositions for controlling surface topography and binding reactivity in functionalized liposomes
AU2007307846A1 (en) * 2006-10-06 2008-04-17 Polytechnic Institute Of Nyu pH sensitive liposome composition
JP5080779B2 (ja) * 2006-10-25 2012-11-21 テルモ株式会社 リポソーム製剤の製造方法
WO2008070009A2 (en) * 2006-12-01 2008-06-12 Alza Corporation Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes
EP1932517A3 (en) * 2006-12-11 2008-07-16 Universiteit Utrecht Holding B.V. Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof
WO2008079240A1 (en) * 2006-12-19 2008-07-03 Alza Corporation Use of liposome-entrapped agents for treating tumors
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
WO2008094959A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
CA2708028A1 (en) 2007-12-05 2009-06-11 Marval Biosciences, Inc. Nano-scale contrast agents and methods of use
DE102008036227A1 (de) * 2008-08-02 2010-02-04 Volkswagen Ag Verstellkinematik für eine Armlehne
CN101601642A (zh) * 2009-06-30 2009-12-16 沈阳药科大学 一种囊泡类给药系统及其应用
JP5785175B2 (ja) 2009-10-26 2015-09-24 石葯集団中奇制葯技▲術▼（石家庄）有限公司 スルホブチルエーテルシクロデキストリン塩を含有する内水相を有するリポソーム
US11357728B2 (en) 2009-10-26 2022-06-14 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt
KR101780915B1 (ko) 2009-12-03 2017-09-21 지앙수 헨그루이 메디슨 컴퍼니 리미티드 이리노테칸 또는 그의 하이드로클로라이드의 리포좀 및 그의 제조 방법
WO2011119995A2 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
US20130337051A1 (en) * 2011-03-01 2013-12-19 To-Bbb Holding B.V. Advanced active liposomal loading of poorly water-soluble substances
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
CN103655477B (zh) * 2012-09-03 2017-06-23 唐为钢 一种恩替卡韦高密度脂蛋白包封制剂及其制备方法和用途
MX2015005992A (es) 2012-11-20 2016-03-07 Spectrum Pharmaceuticals Inc Metodo mejorado para la preparacion de la vincristina liposomal encapsulada para el uso terapeutico.
US10220095B2 (en) * 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
WO2015061206A2 (en) 2013-10-21 2015-04-30 North Carolina State University Methods and constructs for compound delivery
CN104367550A (zh) * 2014-11-18 2015-02-25 南京华威医药科技开发有限公司 一种贝洛替康长循环纳米脂质体及其制备方法
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
US10123973B2 (en) * 2015-06-11 2018-11-13 Mashhad University Of Medical Science Liposome composition for cancer treatment
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
WO2017031442A1 (en) 2015-08-20 2017-02-23 Merrimack Pharmaceuticals, Inc. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
EP3791876A1 (en) 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
CN108136031B (zh) * 2015-10-07 2022-02-18 盐水港精糖株式会社 包含紫杉烷化合物的脂质体
EP3362049A1 (en) 2015-10-16 2018-08-22 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
KR20190077441A (ko) 2016-11-02 2019-07-03 입센 바이오팜 리미티드 리포솜성 이리노테칸, 옥살리플라틴, 5-플루오로우라실 (및 류코보린)을 포함하는 조합 요법을 사용하는 위암 치료
EP3603620A4 (en) 2017-03-31 2020-03-25 FUJIFILM Corporation LIPOSOME COMPOSITION AND PHARMACEUTICAL COMPOSITION
DK3811931T3 (da) 2018-06-20 2024-09-30 Fujifilm Corp Kombinationslægemiddel indeholdende en liposomsammensætning, der indkapsler et lægemiddel, og en immun-checkpoint-hæmmer
TWI837189B (zh) 2018-10-01 2024-04-01 日商富士軟片股份有限公司 包含內含藥物之脂質體組成物及鉑製劑之組合醫藥
EP4349338A4 (en) 2021-05-24 2024-09-04 FUJIFILM Corporation TREATMENT AGENT
JPWO2022250013A1 (da) 2021-05-24 2022-12-01

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1270198C (en) * 1984-08-08 1990-06-12 Marcel B Bally ENCAPSULATION OF ANTINEOPLASTIC AGENTS IN LIPOSONES
US5244903A (en) * 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE4119981C1 (da) 1991-06-18 1993-01-21 Fa. Carl Freudenberg, 6940 Weinheim, De
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
AU6832794A (en) 1993-05-19 1994-12-12 Liposome Company, Inc., The Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer
EP0721328A4 (en) * 1993-09-27 1997-09-17 Smithkline Beecham Corp CAMPTOTHECIN FORMULATIONS
JP2001501173A (ja) 1996-08-23 2001-01-30 アルザ コーポレイション シスプラチン化合物を含有するリポソーム
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
AU4990397A (en) * 1996-10-22 1998-05-15 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
NZ503293A (en) * 1997-09-16 2002-09-27 Nexstar Pharmaceuticals Inc Liposomal camptothecin formulations also comprising at least one phospholipid
IL142573A0 (en) * 1998-09-16 2002-03-10 Alza Corp Liposome-entrapped topoisomerase inhibitors

Also Published As

Publication number Publication date
ATE238039T1 (de) 2003-05-15
EP1121102B1 (en) 2003-04-23
JP2002527466A (ja) 2002-08-27
AU1118900A (en) 2000-05-08
DE69907243D1 (de) 2003-05-28
BR9914601A (pt) 2001-10-23
IL142573A0 (en) 2002-03-10
NZ511112A (en) 2003-11-28
CN1205923C (zh) 2005-06-15
KR20010075639A (ko) 2001-08-09
NO20011844L (no) 2001-04-10
AU774715B2 (en) 2004-07-08
US7279179B2 (en) 2007-10-09
CN1323199A (zh) 2001-11-21
US6465008B1 (en) 2002-10-15
ZA200103063B (en) 2001-10-18
EP1121102A1 (en) 2001-08-08
NO20011844D0 (no) 2001-04-10
DE69907243T2 (de) 2004-02-19
CA2346879A1 (en) 2000-04-27
KR100679906B1 (ko) 2007-02-07
US20020146450A1 (en) 2002-10-10
PT1121102E (pt) 2003-09-30
US20050106231A1 (en) 2005-05-19
WO2000023052A1 (en) 2000-04-27
US20030133973A1 (en) 2003-07-17
US6355268B1 (en) 2002-03-12
ES2198970T3 (es) 2004-02-01
US7244449B2 (en) 2007-07-17

Similar Documents

Publication Publication Date Title
DK1121102T3 (da) Liposomindesluttede topoisomeraseinhibitorer
DE69725747D1 (de) Liposome enthaltend cisplatin
IL138685A0 (en) Liposome composition and method for administering a quinolone
RU94045285A (ru) Композиция против угрей с одновременным лечением поверхностных и глубоких слоев кожи и ее применение
PT932391E (pt) Composicao lipossomal fusogenica e metodo
ES2136883T3 (es) Nueva formulacion mejorada de aminoglucosido para administracion en forma de aerosol.
PT973497E (pt) Dispositivo transportador farmaceutico adequado para administracao de compostos farmaceuticos a superficies mucosas
ES2131190T3 (es) Composicion que contiene efectores de circulacion mejorada y procedimiento de utilizacion de la indicada composicion.
ES2275716T3 (es) Composicion farmaceutica de liberacion transdermica.
WO2001045641A8 (en) Inhibitors of thrombin induced platelet aggregation
IL120317A (en) Ciprofloxacin-hydrocortisone suspension
ATE378060T1 (de) Verbessertes angereichertes blutplättchen wundheilmittel
EP1140022B8 (en) Method of administering a compound to multi-drug resistant cells
CY1107923T1 (el) Τυποποιησεις ελεγχομενης απελευθερωσης χορηγουμενες απο του στοματος
ES2174533T3 (es) Uso de una mezcla de un diol y un acido alfa-hidroxi para el tratamiento de enfermedades de la piel hiperqueratoticas.
ES2184341T3 (es) Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio.
ES2176702T3 (es) Antimicoticos con alta liberacion de sustancia activa.
ATE251894T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung
DE69635806D1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
AR004330A1 (es) Uso de inhibidores de colinesterasa en el tratamiento de xerostomia
ES2141548T3 (es) Preparado farmaceutico de superficie estabilizada para su aplicacion sobre la piel.
NZ328198A (en) a pharmaceutical composition containing hydroxyzine and a serotonin uptake inhibitor
NO991047D0 (no) Transdermal terapeutisk tilnµrming involverende en kombinasjon av aktive substanser inneholdende °striol
IT1280863B1 (it) Procedimento per produrre una forma attiva di incenso e relativo uso dell'incenso stesso.
CO4750616A1 (es) Hilo dental